Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed–refractory multiple myeloma

Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety

(2010) Sung Sook Lee et al.   ANNALS OF HEMATOLOGY

Efficacy and safety of once-weekly bortezomib in multiple myeloma patients

(2010) S. Bringhen et al.   BLOOD

Weekly Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone Is a Safe and Effective Therapy for Elderly Patients With Relapsed/Refractory Multiple Myeloma

(2010) Alessandro Gozzetti et al.   Clinical Lymphoma Myeloma & Leukemia

Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial

(2010) Maria-Victoria Mateos et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib As Induction Before Autologous Transplantation, Followed by Lenalidomide As Consolidation-Maintenance in Untreated Multiple Myeloma Patients

(2010) Antonio Palumbo et al.   JOURNAL OF CLINICAL ONCOLOGY

Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted Myeloma

(2010) Marco Ladetto et al.   JOURNAL OF CLINICAL ONCOLOGY

Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma

(2010) A Palumbo et al.   LEUKEMIA

Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone

(2010) H Avet-Loiseau et al.   LEUKEMIA

Impact of cytogenetics in patients with relapsed or refractory multiple myeloma treated with bortezomib: Adverse effect of 1q21 gains

(2010) Hong Chang et al.   LEUKEMIA RESEARCH

Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study

(2009) Yeo-Kyeoung Kim et al.   ANNALS OF HEMATOLOGY

How I treat multiple myeloma in younger patients

(2009) A. K. Stewart et al.   BLOOD

Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom)

(2009) S. Knop et al.   BLOOD

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma

(2009) P. Richardson et al.   BLOOD

Consolidation Therapy With Low-Dose Thalidomide and Prednisolone Prolongs the Survival of Multiple Myeloma Patients Undergoing a Single Autologous Stem-Cell Transplantation Procedure

(2009) Andrew Spencer et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-term outcome in relapsed and refractory multiple myeloma treated with thalidomide. Balancing efficacy and side-effects

(2009) Alessandro Corso et al.   LEUKEMIA RESEARCH

The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma

(2008) Ruben Niesvizky et al.   BRITISH JOURNAL OF HAEMATOLOGY

The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma

(2008) Stefania Ciolli et al.   BRITISH JOURNAL OF HAEMATOLOGY

Phase I-II Trial of Bortezomib Plus Oral Cyclophosphamide and Prednisone in Relapsed and Refractory Multiple Myeloma

(2008) Donna E. Reece et al.   JOURNAL OF CLINICAL ONCOLOGY

The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis

(2008) E Terpos et al.   LEUKEMIA